Showing 1251-1260 of 23044 results for "".
Risk Reduction with GLP-1 RAs in Individuals with ASCVD and T2D: 2025 Update
https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many indivIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
https://reachmd.com/programs/neurofrontiers/individualized-cognitive-stimulation-mild-alzheimers/40001/Real-World Adaptation of Trial Protocols
https://evolvemeded.com/specialty/general-ophthalmology/Real-World-Adaptation-of-Trial-Protocols-2510/33130/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Beyond Durability - What Biomarkers Reveal About Disease Control
https://reachmd.com/programs/cme/Beyond-Durability-What-Biomarkers-Reveal-About-Disease-Control-2510/33104/Hear about new biomarkers for assessing retinal disease activity and their clinical significance when using of second-generation agents.Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
https://reachmd.com/programs/cme/chairpersons-perspective-evidence-informed-clinical-decision-making-in-her2-overexpressed-and-trop2-targeted-nsclc/39894/Study HER2 IHC testing, efficacy, and NCCN guidance supporting ADC sequencing for HER2-overexpressed NSCLC and TROP2-directed ADCs for EGFR-TKI–resistant NSCLC.Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
https://reachmd.com/programs/cme/reimagining-lung-cancer-treatment-a-journey-through-new-and-emerging-therapeutics-related-to-the-care-of-patients-with-small-cell-and-non-small-cell-lung-cancer/35653/Reimagine lung cancer care—discover how new and emerging therapies are reshaping the treatment of SCLC and NSCLCGlobal Perspectives on New Data in Type 2 Diabetes — Congress-to-Clinic Insights From ADA and EASD 2025
https://reachmd.com/programs/cme/global-perspectives-on-new-data-in-type-2-diabetes-congress-to-clinic-insights-from-ada-and-easd-2025/36231/On-demand webcast with expert faculty presentation highlighting key studies in diabetes from the 2025 American Diabetes Association and European Association for the Study of Diabetes annual meetings.How Biosimilars Can Enhance the Lives—and Savings—of Rheumatoid Arthritis Patients
https://reachmd.com/programs/clinicians-roundtable/how-biosimilars-can-enhance-the-livesand-savingsof-rheumatoid-arthritis-patients/27068/Dive into a study focused on biosimilars and why they could be integral to treating patients with rheumatoid arthritis.CDC - TB & HIV: A Deadly Duo, Part 1
https://reachmd.com/programs/grand-rounds-nation/cdc-tb-hiv-a-deadly-duo-part-1/6390/The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death rateCDC - TB & HIV: A Deadly Duo, Part 3
https://reachmd.com/programs/grand-rounds-nation/cdc-tb-hiv-a-deadly-duo-part-3/6392/The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB death